Table 1: Summary of completed NSCLC immuno-therapy trials.
Immuno-therapy |
Target |
Pt No. |
Stage |
Results |
Stage I-III disease |
||||
MAGE-A3 |
MAGE-A3 |
182 |
IB/II following complete resection |
HR for DFS = 0.76 (95% CI: 0.48-1.21), HR for OS = 0.81 (95% CI: 0.47-1.40) with MAGE-A3 compared to SOC [5] |
Stage III B-IV disease |
||||
BLP-25 |
MUC1 |
171 |
IIIB/IV after 1st line chemotherapy |
3 yr. OS 31% for BLP-25 and 17% for BSC (P = 0.035) |
Belagenpimatucel-L |
TGF-β2 |
75 |
II/IIIA/IIIB/IV after completion of therapy |
Superior MS for high vaccine doses group vs. low vaccine doses group (P = 0.0069) [8] |
EGF |
Epidermal growth factor |
80 |
IIIB/IV after first-line chemotherapy |
MS 11.7 months with GAR and 3.6 months with PAR (P = 0.0002) [9] |
TG4010 |
MUC1 |
148 |
IIIB/IV with 1st line chemotherapy |
6-months PFS 43.2% for TG4010 vs. 35.1% for chemotherapy alone (P = 0.307) [10] |
Ipilimumab |
CTLA-4 |
204 |
IIIB/IV or recurrent disease in combination with first-line chemotherapy |
Immune-related PFS 5.7 months for phased ipilimumab + chemotherapy vs. 4.6 months for placebo + chemotherapy (HR 0.72; P = 0.05) [11] |
Nivolumab |
PD-1 |
296 (122 NSCLC) |
IV after completion of first-line chemotherapy |
OR in 6 (33%) out of 18 with squamous cell histology; OR in 7 (12%) out of 56 with non-squamous histology [12] |
BMS-936559 |
PD-L1 |
207 (75 NSCLC) |
IV after completion of first-line chemotherapy |
OR in 4 (11%) of 36 non-squamous histology; OR in 1 (8%) of 13 squamous histology [13] |
BSC: Best Supportive Care; GAR: Good Antibody Response; HR: Hazard Ration; MS: Median Survival; NSCLC: Non-Small Cell Lung Cancer; OR: Overall Response; PAR: Poor Antibody Response; PFS: Progression-Free Survival; Pt: Patients; RR: Response Rate; SOC: Standard of Care